Holen Sie sich die Stockscreener-App
147.60
2.90%
4.16
Handel nachbörslich:
147.32
-0.28
-0.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$143.44
Offen:
$145.1
24-Stunden-Volumen:
6.72M
Relative Volume:
0.91
Marktkapitalisierung:
$183.02B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
20.08
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+8.63%
1M Leistung:
+9.92%
6M Leistung:
-2.33%
1J Leistung:
+25.11%
1-Tages-Spanne:
$144.30
$148.97
1-Wochen-Bereich:
$135.91
$148.97
52-Wochen-Spanne:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
147.60 | 177.86B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,280.34 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.41 | 653.35B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.97 | 457.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
152.20 | 333.49B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
160.31 | 293.76B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences Inc Stock (GILD) Moved Up by 3.66% on Aug 19: A Full Analysis - TradingKey
Gilead Sciences (GILD) CFO Andrew Dickinson Sells 3,000 Shares - GuruFocus
Zacks Research Forecasts Higher Earnings for Gilead Sciences - MarketBeat
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? - The Motley Fool
Meeder Advisory Services Inc. Invests $4.42 Million in Gilead Sciences, Inc. $GILD - MarketBeat
M. Kulyk & Associates LLC Buys New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Pallas Capital Advisors LLC Invests $940,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Great Lakes Advisors LLC Makes New $127.25 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
13,735 Shares in Gilead Sciences, Inc. $GILD Purchased by Empirical Asset Management LLC - MarketBeat
840,400 Shares in Gilead Sciences, Inc. $GILD Purchased by Danske Bank A S - MarketBeat
Gilead Sciences Insider Sold Shares Worth $3,853,908, According to a Recent SEC Filing - marketscreener.com
Gilead Sciences CFO Andrew Dickinson sells $415k in shares - Investing.com
Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences chief comm & corp aff officer sells $3.85m stock - Investing.com
Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of Stock - MarketBeat
Gilead (NASDAQ: GILD) CFO sells shares under 10b5-1 plan - Stock Titan
Gilead Sciences Inc (GILD) Stock Up 3.2% but GF Value Says Overv - GuruFocus
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Gilead SciencesGISStock Price & News - The Motley Fool
Is Gilead's Expanding HIV Portfolio a Growth Catalyst? - TradingView
Gilead Sciences Inc Stock (GILD) Moved Up by 3.14% on Aug 18: Drivers Behind the Movement - TradingKey
Gilead gains as investors focus on stronger HIV momentum and a near-term FDA catalyst - Quiver Quantitative
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited. - AOL.com
Texas Capital Bank Wealth Management Services Inc Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Meeder Asset Management Inc. Invests $17.12 Million in Gilead Sciences, Inc. $GILD - MarketBeat
34,701 Shares in Gilead Sciences, Inc. $GILD Purchased by Occidental Asset Management LLC - MarketBeat
Perigon Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Makes New $398.90 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
21,689 Shares in Gilead Sciences, Inc. $GILD Purchased by Citizens Financial Group Inc. RI - MarketBeat
41,571 Shares in Gilead Sciences, Inc. $GILD Acquired by Commerzbank Aktiengesellschaft FI - MarketBeat
Grandfield & Dodd LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
GSA Capital Partners LLP Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
121,844,108 Shares in Gilead Sciences, Inc. $GILD Purchased by BlackRock Inc. - MarketBeat
Gilead Sciences Earnings Call Highlights Strong Core Growth - The Globe and Mail
TRADEMARK—4th Cir.: Gilead Sciences secures affirmance of injunction blocking foreign-market Biktarvy drug imports - VitalLaw.com
Gilead Sciences (NASDAQ: GILD) insider plans $3.9M share sale - Stock Titan
Gilead Sciences (NASDAQ: GILD) insider plans another 3,000-share sale - Stock Titan
In Win for Gilead, Fourth Circuit Affirms Injunction Blocking Drug Importation Scheme - IPWatchdog.com
Gilead yanks out a thorn in its side in major court ruling - thestreet.com
Simplicity Wealth LLC Invests $1.36 Million in Gilead Sciences, Inc. $GILD - MarketBeat
20,266 Shares in Gilead Sciences, Inc. $GILD Acquired by OneDigital Investment Advisors LLC - MarketBeat
Gilead Sciences stock holds steady as Q2 2026 loss sharpens focus on oncology strategy - ad-hoc-news.de
N.E.W. Advisory Services LLC Takes $1.38 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
HBK Sorce Advisory LLC Invests $4.01 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Johnson Wealth Management LLC Makes New $2.41 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Analysis: A Promising 13.77% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Flputnam Investment Management Co. Invests $8.96 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Global Retirement Partners LLC Purchases Shares of 34,604 Gilead Sciences, Inc. $GILD - MarketBeat
442,000 Shares in Gilead Sciences, Inc. $GILD Acquired by Alberta Investment Management Corp - MarketBeat
AMG National Trust Bank Purchases Shares of 26,675 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (NASDAQ: GILD) CCO sells 28,000 shares under 10b5-1 plan - Stock Titan
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Aug 17 '26 |
Option Exercise |
67.07 |
25,000 |
1,676,773 |
146,234 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Aug 17 '26 |
Sale |
137.64 |
28,000 |
3,853,908 |
118,234 |
3.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):